Chronic cough in idiopathic pulmonary fibrosis (IPF) is one of the most debilitating and treatment-resistant symptoms patients face, yet until recently no approved pharmacological option existed to meaningfully address it. A dose-response clarification from the CORAL study authors offers a meaningful signal for clinicians managing this difficult symptom burden.
The CORAL trial evaluated nalbuphine extended-release (ER) at three doses — 27 mg, 54 mg, and 108 mg twice daily — against placebo in IPF patients. Both the 54 mg and 108 mg twice-daily arms achieved statistically significant reductions in objective cough frequency (measured electronically) as well as patient-reported cough frequency and severity. The 27 mg twice-daily dose, while improving objective cough counts, failed to consistently move patient-reported outcomes, leading investigators to classify it as only minimally effective — a distinction that matters clinically, as symptom perception is central to quality of life in a disease with no curative treatment.
This dose-response finding adds important nuance to the IPF treatment landscape. Nalbuphine is a kappa-opioid receptor agonist and partial mu-opioid antagonist, a pharmacological profile that may suppress cough via central mechanisms while carrying a lower addiction and respiratory depression risk than traditional opioids — a relevant consideration for a patient population already compromised in lung function. IPF cough has long resisted standard antitussives, and prior trials of agents like gefapixant in IPF-specific populations have shown limited benefit. The CORAL data represent one of the more rigorous dose-characterization efforts in this space.
Limitations worth noting: this is a reply letter rather than a primary data publication, meaning full cohort demographics, follow-up duration, and adverse event profiles require consultation of the original CORAL report. The finding is nonetheless clinically directional — the 54 mg twice-daily dose appears to be the practical threshold where both objective and subjective cough measures align.